Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMG324Y)

Drug Name
AMG 145 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hypercholesterolaemia 5C80.0 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMG324Y

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) TTBRG7E PCSK9_HUMAN Modulator [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hypercholesterolaemia
ICD Disease Classification 5C80.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01854918) Open Label Study of Long Term Evaluation Against LDL-C Trial-2. U.S. National Institutes of Health.
2 PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40.